Huvepharma has received approval and has released a trivalent oocyst vaccine for turkeys. The product incorporates three species, Eimeria adenoeides, E. meleagrimitis and E. gallopavonis.
The Huvepharma turkey coccidiosis vaccine is intended to provide optimum protection with minimal post-vaccination reaction. The oocyst suspension can be administered orally or by hatchery spray.
According to Dr. Steven Clark, Turkey Technical Services Manager at Huvepharma, “Turkey coccidiosis continues to be a top concern of the industry.” He added, “We are proud to produce another approach to control coccidiosis in turkeys.”
The Huvepharma turkey coccidiosis vaccine is the only available product providing protection against three Eimeria species that impact turkeys. Coccidiosis interacts with viral, protozoal and bacterial intestinal pathogens. Coccidiosis is a significant detractor from live performance and hence profitability.
|